Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia.
Unit of Geriatrics and Gerontology and Rare Diseases, Department of Internal Medicine and Public Health, University of Bari, Polyclinic, Bari, Italy.
Patrizia
P
Suppressa
Suppressa
S
Patrizia
Arcangelo
A
Liso
Liso
L
Arcangelo
Carlo
C
Sabbà
Sabbà
S
Carlo
D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D005148:Facial Dermatoses / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab